-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the data query of Wencai, an investment and research platform of Flush, from the beginning to the end of 2021, there are 357 listed companies whose stock prices have an annual increase of more than 100%, and 105 stocks that have an annual increase of more than 200%.
Among them, * ST Hemei in 2021 The increase was the first, as high as 1111.
54%
.
The annual growth rate of 357 stocks has doubled, and pharmaceutical equipment companies have performed well (Source: Pharmaceutical Network) Judging from the 357 stocks that have doubled the annual growth rate, they are mainly concentrated in pharmaceutical biology, electronics, chemical and other industries
.
According to the author's incomplete statistics, in the pharmaceutical and biological industry, there are at least 19 stocks with an annual increase of more than 100%, including Jiu'an Medical, Gongdong Medical, Boren Medical, Rejing Bio, Tuoxin Pharmaceutical, etc.
Among them, Jiu'an Medical, Six stocks including Gongdong Medical and Rejing Biology rose by more than 200%
.
From January 4, 2021 to December 31, 2021, the stock price range of Jiu'an Medical increased by 217.
26%, and the current price is 68.
44 yuan, an increase of 10%
.
Gongdong Medical followed closely.
From January 4, 2021 to December 31, 2021, the annual increase of the stock price reached 258.
55%, and the current price was 145.
03 yuan, an increase of 0.
62%
.
In addition, the annual growth rate of Rejing Bio and Tuoxin Pharmaceutical also exceeded 200%
.
It is worth mentioning that the stock price performance of pharmaceutical equipment companies in 2021 is also very dazzling.
For example, individual stocks including Tofflon, Canaan Technology, Chutian Technology, Xinhua Medical, and Tailin Biology have an annual increase of more than 100%
.
From January 4, 2021 to December 31, 2021, Tofflon's share price range rose as high as 217.
26%
.
According to the data, Tofflon is a domestic pharmaceutical equipment giant and a domestic freeze dryer equipment manufacturing giant.
Its main businesses include pharmaceutical equipment sector, medical technology and technology sector, and food equipment engineering sector
.
In 2021, Tofflon has also attracted the attention of a large number of investment institutions, including many large institutions such as Hillhouse, Ruiyuan, and Huitianfu.
.
In addition, the stock price of Canaan Technology will increase by 154.
22% in 2021, and the three stocks of Chutian Technology, Xinhua Medical, and Tailin Bio will increase by 137.
43%, 128.
05%, and 104.
42% respectively
.
Behind the sharp rise in the stock prices of these pharmaceutical equipment companies, the analysis believes that there are several factors that support them, including the company's fundamentals such as rising performance, rapid growth, large market demand, and significant improvement in the entire industry
.
As far as the performance of pharmaceutical machine companies in 2021 is concerned, in the first three quarters of 2021, many pharmaceutical machine companies have achieved rapid growth in performance, and their transcripts have performed well
.
For example, in the first nine months of 2021, Tofflon achieved operating income of about 2.
882 billion yuan, a year-on-year increase of 54.
61%; net profit of about 558 million yuan, a year-on-year increase of 93.
69%; basic earnings per share of 0.
8883 yuan, a year-on-year increase of 93.
70%
.
On January 10, Tofflon also released the 2021 annual performance forecast.
It is expected that the performance will rise in the same direction, and the net profit during the reporting period will increase by 65%-95% compared with the same period of the previous year
.
As for the reason for the positive performance, Tofflon attributed it to the fact that during the reporting period, the company vigorously promoted the layout and investment of the three major sectors.
At the same time, the new products and new markets of the company's business sector layout over the years have gradually shown results, injections, solid preparations and other sectors.
Steady growth; rapid growth in sectors such as biological macromolecules and cell equipment
.
Tailin Biotech also announced its 2021 performance forecast recently, and the company also expects its 2021 performance to rise in the same direction
.
During the reporting period, the net profit was 58.
07 million yuan to 72.
58 million yuan, an increase of 20.
02%-50% over the same period of the previous year
.
The main reason for the increase in performance was that the company's sales revenue continued to grow
.
For another example, Chutian Technology also set a new high in performance in the first nine months of 2021, achieving an operating income of 3.
682 billion yuan, a year-on-year increase of 67.
24%; a net profit of 401 million yuan, a year-on-year increase of 723.
53%, which is the full year net profit in 2020.
Twice as much, it can be said to be quite rewarding
.
From the background of the entire pharmaceutical machine industry, the domestic pharmaceutical equipment industry is entering a stage of rapid development, and enterprises continue to undertake new opportunities
.
On the one hand, with the vigorous development of innovative drugs and biological drugs, the demand in the upstream pharmaceutical equipment market will also continue to expand
.
According to Frost & Sullivan's forecast, the scale of China's biopharmaceutical market will rapidly expand at an average compound annual growth rate of 18% in the next few years, reaching 59 billion yuan by 2030
.
At the same time, with the advancement of new technologies such as artificial intelligence and 5G, the pharmaceutical industry has accelerated its transformation and upgrading, and the market is also in urgent need of higher-end pharmaceutical equipment, which has brought more opportunities to the pharmaceutical machine industry
.
On the other hand, since 2020, domestic innovative pharmaceutical companies, vaccine companies and other pharmaceutical companies that originally relied on imported equipment, due to factors such as delayed delivery of imported equipment, have begun to shift their targets to domestic cost-effective pharmaceutical machines and equipment.
Given the high recognition of domestic equipment, the pace of domestic substitution of imports is expected to accelerate in the future.
In this context, powerful giants are generally favored by the industry
.
Among them, * ST Hemei in 2021 The increase was the first, as high as 1111.
54%
.
The annual growth rate of 357 stocks has doubled, and pharmaceutical equipment companies have performed well (Source: Pharmaceutical Network) Judging from the 357 stocks that have doubled the annual growth rate, they are mainly concentrated in pharmaceutical biology, electronics, chemical and other industries
.
According to the author's incomplete statistics, in the pharmaceutical and biological industry, there are at least 19 stocks with an annual increase of more than 100%, including Jiu'an Medical, Gongdong Medical, Boren Medical, Rejing Bio, Tuoxin Pharmaceutical, etc.
Among them, Jiu'an Medical, Six stocks including Gongdong Medical and Rejing Biology rose by more than 200%
.
From January 4, 2021 to December 31, 2021, the stock price range of Jiu'an Medical increased by 217.
26%, and the current price is 68.
44 yuan, an increase of 10%
.
Gongdong Medical followed closely.
From January 4, 2021 to December 31, 2021, the annual increase of the stock price reached 258.
55%, and the current price was 145.
03 yuan, an increase of 0.
62%
.
In addition, the annual growth rate of Rejing Bio and Tuoxin Pharmaceutical also exceeded 200%
.
It is worth mentioning that the stock price performance of pharmaceutical equipment companies in 2021 is also very dazzling.
For example, individual stocks including Tofflon, Canaan Technology, Chutian Technology, Xinhua Medical, and Tailin Biology have an annual increase of more than 100%
.
From January 4, 2021 to December 31, 2021, Tofflon's share price range rose as high as 217.
26%
.
According to the data, Tofflon is a domestic pharmaceutical equipment giant and a domestic freeze dryer equipment manufacturing giant.
Its main businesses include pharmaceutical equipment sector, medical technology and technology sector, and food equipment engineering sector
.
In 2021, Tofflon has also attracted the attention of a large number of investment institutions, including many large institutions such as Hillhouse, Ruiyuan, and Huitianfu.
.
In addition, the stock price of Canaan Technology will increase by 154.
22% in 2021, and the three stocks of Chutian Technology, Xinhua Medical, and Tailin Bio will increase by 137.
43%, 128.
05%, and 104.
42% respectively
.
Behind the sharp rise in the stock prices of these pharmaceutical equipment companies, the analysis believes that there are several factors that support them, including the company's fundamentals such as rising performance, rapid growth, large market demand, and significant improvement in the entire industry
.
As far as the performance of pharmaceutical machine companies in 2021 is concerned, in the first three quarters of 2021, many pharmaceutical machine companies have achieved rapid growth in performance, and their transcripts have performed well
.
For example, in the first nine months of 2021, Tofflon achieved operating income of about 2.
882 billion yuan, a year-on-year increase of 54.
61%; net profit of about 558 million yuan, a year-on-year increase of 93.
69%; basic earnings per share of 0.
8883 yuan, a year-on-year increase of 93.
70%
.
On January 10, Tofflon also released the 2021 annual performance forecast.
It is expected that the performance will rise in the same direction, and the net profit during the reporting period will increase by 65%-95% compared with the same period of the previous year
.
As for the reason for the positive performance, Tofflon attributed it to the fact that during the reporting period, the company vigorously promoted the layout and investment of the three major sectors.
At the same time, the new products and new markets of the company's business sector layout over the years have gradually shown results, injections, solid preparations and other sectors.
Steady growth; rapid growth in sectors such as biological macromolecules and cell equipment
.
Tailin Biotech also announced its 2021 performance forecast recently, and the company also expects its 2021 performance to rise in the same direction
.
During the reporting period, the net profit was 58.
07 million yuan to 72.
58 million yuan, an increase of 20.
02%-50% over the same period of the previous year
.
The main reason for the increase in performance was that the company's sales revenue continued to grow
.
For another example, Chutian Technology also set a new high in performance in the first nine months of 2021, achieving an operating income of 3.
682 billion yuan, a year-on-year increase of 67.
24%; a net profit of 401 million yuan, a year-on-year increase of 723.
53%, which is the full year net profit in 2020.
Twice as much, it can be said to be quite rewarding
.
From the background of the entire pharmaceutical machine industry, the domestic pharmaceutical equipment industry is entering a stage of rapid development, and enterprises continue to undertake new opportunities
.
On the one hand, with the vigorous development of innovative drugs and biological drugs, the demand in the upstream pharmaceutical equipment market will also continue to expand
.
According to Frost & Sullivan's forecast, the scale of China's biopharmaceutical market will rapidly expand at an average compound annual growth rate of 18% in the next few years, reaching 59 billion yuan by 2030
.
At the same time, with the advancement of new technologies such as artificial intelligence and 5G, the pharmaceutical industry has accelerated its transformation and upgrading, and the market is also in urgent need of higher-end pharmaceutical equipment, which has brought more opportunities to the pharmaceutical machine industry
.
On the other hand, since 2020, domestic innovative pharmaceutical companies, vaccine companies and other pharmaceutical companies that originally relied on imported equipment, due to factors such as delayed delivery of imported equipment, have begun to shift their targets to domestic cost-effective pharmaceutical machines and equipment.
Given the high recognition of domestic equipment, the pace of domestic substitution of imports is expected to accelerate in the future.
In this context, powerful giants are generally favored by the industry
.
